How many insider trades does FilingIQ track for PHAT?

FilingIQ tracks 288 Form 4 insider transactions for PHAT (Phathom Pharmaceuticals, Inc.), covering filings from Oct 29, 2019 onwards. 6 of those were filed in the last 90 days.

Are PHAT insiders net buyers or net sellers?

Across the full Form 4 history for PHAT, 30 transactions (10%) were open-market purchases and 166 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PHAT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PHAT in?

Phathom Pharmaceuticals, Inc. (PHAT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $950.98M.

PHAT insider trading

Healthcare

Phathom Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

288

Last 90 days

Buys / sells

10% / 58%

Market cap

$950.98M

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Company website: www.phathompharma.com

PHAT insider activity at a glance

FilingIQ has scored 288 insider transactions for PHAT since Oct 29, 2019. The most recent filing in our index is dated Mar 10, 2026.

Across the full history, 30 open-market purchases and 166 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PHAT insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PHAT trades on FilingIQ Raw filings on SEC EDGAR

Latest PHAT Form 4 filings

Henderson Molly CFO and CBO

S Nov 1, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding PHAT

Frazier Life Sciences Management, L.P.

$94.33M · 5.9% of AUM

Simplify Asset Management Inc.

$9.44M · 0.4% of AUM

Decheng Capital Management III (Cayman), LLC

$8.81M · 2.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for PHAT?: FilingIQ tracks 288 Form 4 insider transactions for PHAT (Phathom Pharmaceuticals, Inc.), covering filings from Oct 29, 2019 onwards. 6 of those were filed in the last 90 days.
Are PHAT insiders net buyers or net sellers?: Across the full Form 4 history for PHAT, 30 transactions (10%) were open-market purchases and 166 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PHAT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PHAT in?: Phathom Pharmaceuticals, Inc. (PHAT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $950.98M.

Methodology & sources

Every PHAT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.